Advanced glycation end products and the progressive course of renal disease
Authors:
- August HeidlandAHAugust Heidland
- Katarina SebekovaKSKatarina Sebekova
- Reinhard SchinzelRSReinhard Schinzel
- 1 October 2001
- journal article
- review article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 38 (4) , S100-S106
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Advanced glycation end products (AGEs)‐induced expression of TGF‐β1 is suppressed by a protease in the tubule cell line LLC‐PK1Nephrology Dialysis Transplantation, 2001
- Importance of oxidatively modified proteins in chronic renal failureKidney International, 2001
- Differences in the modulating potential of advanced glycation end product (AGE) peptides versus AGE proteinsKidney International, 2001
- Nitric oxide inhibits the formation of advanced glycation end productsKidney International, 2000
- Amadorins: Novel Post-Amadori Inhibitors of Advanced Glycation ReactionsBiochemical and Biophysical Research Communications, 1999
- Immunocytochemical detection of advanced glycated end products in rat renal tissue as a function of age and diabetesKidney International, 1998
- PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end productsKidney International, 1995
- Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failureThe Lancet, 1994
- Early glycosilation products induce glomerular hyperfiltration in normal ratsKidney International, 1992
- Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic ComplicationsNew England Journal of Medicine, 1988